drugset

drugset / Trial / NCT06299696

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

NCT06299696 ↗

Phase 1 Completed 10 enrolled Vertex Pharmaceuticals Incorporated

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the flavor (basic tastes, aroma, texture, mouthfeel) of VNZ/TEZ/D-IVA fixed dose combination (FDC) granules.

Timeline

Start: 2024-03-26
Primary completion: 2024-04-16
Completion: 2024-04-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	VNZ/TEZ/D-IVA	Unknown	—	Oral

Indications